Marseille 2007
Marseille 2007
Abstract book
Go Back

Abstract #421  -  What can HIV vaccine trials teach us about dissemination? Barriers and motivators to trial participation and future HIV vaccine acceptability among vulnerable communities
Session:
  48.5: Behaviour and prevention (Parallel) on Wednesday @ 08.30-10.30 in CP Chaired by Michael Ross, Marie Preau
Authors:
  Presenting Author:   Dr Peter Newman - University of Toronto, Canada
 
  Additional Authors:  Dr Kathleen Roberts, Ms Lisa Kakinami, Dr Naihua Duan,  
Aim:
Numerous studies have addressed willingness to participate (WTP) in preventive HIV vaccine trials, yet little is known about the acceptability of future HIV vaccines or the applicability of findings regarding WTP to HIV vaccine acceptability. We explored commonalities and differences in perceived barriers and motivators regarding willingness to participate (WTP) in preventive HIV vaccine trials and acceptability of future preventive HIV vaccines among adults from vulnerable communities.
 
Method / Issue:
Fifteen focus groups (9 on HIV vaccine acceptability, 6 on WTP) were conducted with 157 participants (27% African American, 51% Latino, 19% white; 47% women; 51% income <= $10,000) recruited using venue-based sampling from 3 needle exchange programs, 2 Latino and 1 African-American community health center, and 3 gay community centers in Los Angeles, California, US. Focus groups were audiotaped and transcribed verbatim. Data were analyzed using narrative thematic analysis and Ethnograph qualitative software. Member checking, peer debriefing and triangulation of data sources were used to increase trustworthiness of the findings.
 
Results / Comments:
Barriers common to WTP and future HIV vaccine acceptability were perceived risk of vaccine-induced HIV infection, concerns about false HIV-positives, side effects, uncertain efficacy, mistrust of government and pharmaceutical companies, HIV/AIDS stigma, low perceived HIV risk and relationship issues. Barriers specific to HIV vaccine acceptability included duration of protection, cross-clade protection and cost/access. Protection against HIV infection was a motivator common to WTP and HIV vaccine acceptability.
 
Discussion:
Concerns in common (e.g., undue fears of vaccine-induced infection; social consequences of false HIV-positives; and mistrust) across WTP and HIV vaccine acceptability suggest that clinical trials present significant opportunities to develop and evaluate empirically-based interventions to support the monumental task of future, large-scale HIV vaccine dissemination. Nevertheless, barriers and motivators unique to vaccine acceptability recommend additional consumer-based focus on HIV vaccine dissemination. Motivators for both WTP and vaccine acceptability that may support behavioral disinhibition suggest the need for tailored behavioral interventions for participants in HIV vaccine trials and preventive interventions to be delivered in tandem with future HIV vaccine dissemination.
 
Go Back

  Disclaimer   |   T's & C's   |   Copyright Notice    www.AIDSImpact.com www.AIDSImpact.com